STOCKBIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)Updated 2026-08-16
Here’s whether Moderna, Inc. Common Stock (MRNA) is worth buying in 2026 —
based on weekly-updated price trend, RSI momentum, and return vs.
the S&P 500. Our current read: Bullish.
🟢
Bullish
Positives: trading above the 200-day MA (long-term uptrend intact); above the 50-day MA (medium-term momentum positive); 50-day MA is rising (+4.11% over 10 days); strong 1-year return of +137.2%; 3-month momentum positive (+29.1%). Currently 26.0% off its 52-week high. Score: +6/7.
MRNA is in a confirmed uptrend, trading above both its 50-day ($60.81) and 200-day ($46.48) moving averages. An RSI of 66.4 sits in the neutral zone — momentum is neither stretched nor exhausted. The 1-year return of +137.2% compares to +20.4% for SPY (beat the market by 116.9%). The current 26.0% drawdown from the 52-week high reflects elevated risk for momentum-based strategies.
$10,000 invested 1 year ago→ $23,724 today
vs. S&P 500 (SPY) — same period beat market by 116.9%
1-Year Price Chart
Daily candles
MA-50MA-200UpDown
Signal Check
✓Above 200-day MA ($46.48)
✓Above 50-day MA ($60.81)
✓RSI(14) neutral zone (30–70) — currently 66.4
✓Positive return (+137.2%)
!Within 10% of period high (−26.0%)
Period Range $63.32
$22.28$85.60
RSI (14) 66.4
0 · OversoldOverbought · 100
Key Metrics
Price$63.32
Period Return+137.2%
Period High$85.60
Period Low$22.28
Drawdown−26.0%
MA-50$60.81
MA-200$46.48
RSI (14)66.4
Avg Volume (30d)6.1M
vs. SPYbeat by 116.9%
Return Rank#101 of 1252
Trend Signals
Price is above the 200-day moving average ($46.48)